NRG Therapeutics

To add a bio or update company history, please click update information.

News from NRG Therapeutics

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

8 Sept 2025

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.

NRG Therapeutics

Life Sciences
Stevenage, United Kingdom
£50m
nrgtherapeutics.com
Update Information

More venture news

Big Picture Bio
18 Sept 2026
Big Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences
Eterna Regeneratives
16 Sept 2026
Eterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
Magnitude Biosciences
15 Sept 2026
Magnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms
EquityLife Sciences

NRG Therapeutics

News from NRG Therapeutics

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

More venture news

Big Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies

Eterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair

Magnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms